Patent details

301238 Product Name: Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301238
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2922846
Status:
SPC granted but not yet in force
Application number:
301238
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/23/1718
Marketing Authorization Type:
EEA
Marketing Authorization Date:
27/03/2023
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
24/07/2023
First Marketing Authorization date:
27/03/2023
Grant date:
04/10/2023
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
24/07/2023
SPC/SPC Extension Expiration Date:
26/03/2038
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
24/07/2023
 
 

 

Name:
Bristol-Myers Squibb Company
Address:
Route 206 and Province Line Road, PRINCETON, NJ 08543, United States of America (US)

Agent

Name:
dr. R.C. van Duijvenbode c.s.
From:
24/07/2023
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC
Journal edition number:
41/23
Publication date:
11/10/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

2

Bulletin Heading:
SPC
Journal edition number:
30/23
Publication date:
26/07/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Annual Fee

Annual Fee(s) Due Date:
30/11/2033
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type
04/10/2023 Outgoing Correspondence Decision grant 1 PDF /5/4/1/0/0/0800900145/docs/301238_9_569391l504a.pdf
04/10/2023 Certificate Certificate 1 PDF /5/4/1/0/0/0800900145/docs/301238_10_spcmedcertificate20231004094732003.pdf
24/07/2023 Application Form First filed application form 2 PDF /5/4/1/0/0/0800900145/docs/301238_0_applicationform20230724095447545.pdf
24/07/2023 SPC Documents Annex SPC 4 PDF /5/4/1/0/0/0800900145/docs/301238_1_supplprotectioncertificate20230724095535528.pdf
24/07/2023 SPC Documents Marketing Authorization SPC 3 PDF /5/4/1/0/0/0800900145/docs/301238_2_supplprotectioncertificate20230724103706595.pdf
24/07/2023 SPC Documents Annex SPC 11 PDF /5/4/1/0/0/0800900145/docs/301238_3_supplprotectioncertificate20230724103736115.pdf
24/07/2023 SPC Documents Summary of the characteristics of the product 15 PDF /5/4/1/0/0/0800900145/docs/301238_4_supplprotectioncertificate20230724095844426.pdf
24/07/2023 SPC Documents Annex SPC 2 PDF /5/4/1/0/0/0800900145/docs/301238_5_supplprotectioncertificate20230724095844464.pdf
24/07/2023 SPC Documents Annex SPC 12 PDF /5/4/1/0/0/0800900145/docs/301238_6_supplprotectioncertificate20230724095844497.pdf
24/07/2023 SPC Documents Annex SPC 2 PDF /5/4/1/0/0/0800900145/docs/301238_7_supplprotectioncertificate20230724103821458.pdf
24/07/2023 Outgoing Correspondence Confirmation receipt request 2 PDF /5/4/1/0/0/0800900145/docs/301238_8_557119l174.pdf